New weapon against advanced cancer enters human testing
NCT ID NCT06440005
Summary
This is the first study in people testing a new cancer drug called AGX101. It aims to find a safe and effective dose for patients with advanced solid tumors that have spread or cannot be removed by surgery, and who have no other standard treatment options left. The drug is given through an IV every few weeks, and researchers will closely monitor how patients respond and handle the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Florida Cancer Specialist
RECRUITINGSarasota, Florida, 34232, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Oncology
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Email: •••••@•••••
Contact
-
NEXT Oncology
RECRUITINGFairfax, Virginia, 22031, United States
Contact
Contact Phone: •••-•••-••••
-
Sarah Cannon Research Center
RECRUITINGNashville, Tennessee, 37203, United States
Contact
Contact Email: •••••@•••••
-
USC/Norris Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90033, United States
Contact
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.